[go: up one dir, main page]

PE20051036A1 - PEPTIDE RECEPTOR ANTAGONISTS RELATED TO THE CALCITONIN GENE - Google Patents

PEPTIDE RECEPTOR ANTAGONISTS RELATED TO THE CALCITONIN GENE

Info

Publication number
PE20051036A1
PE20051036A1 PE2004001196A PE2004001196A PE20051036A1 PE 20051036 A1 PE20051036 A1 PE 20051036A1 PE 2004001196 A PE2004001196 A PE 2004001196A PE 2004001196 A PE2004001196 A PE 2004001196A PE 20051036 A1 PE20051036 A1 PE 20051036A1
Authority
PE
Peru
Prior art keywords
alkyl
oxo
calcitonin gene
quinazolin
indol
Prior art date
Application number
PE2004001196A
Other languages
Spanish (es)
Inventor
Guanglin Luo
Ling Chen
Andrew P Degnan
John E Macor
Prasad V Chaturvedula
Charles Mark Conway
Xiang Jun J Jiang
Graham Poindexter
Shikha Vig
George N Karageorge
Xiaojun Han
Rita Civiello
George Tora
Gene M Dubowchik
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34748456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20051036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20051036A1 publication Critical patent/PE20051036A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE V ES -N(R1)(R2), OR4, DONDE R4 ES H, ALQUILO C1-C6, HALOALQUILO C1-C4, ENTRE OTROS; R1 Y R2 SON CADA UNO H, ALQUILO C1-C6, ALQUENILO C2-C6, FENILO, ENTRE OTROS; Q ES (SY)SR3, NH(SY)SR3, NHC(O)(SY)SR3, ENTRE OTROS; R3 ES CICLOALQUILO C3-C7, CARBAZILO, FENILO, ENTRE OTROS; SY ES ALQUILENO C1-C3, ALQUILIDENO C1-C3; S ES 0-1; U ES CH2, NH; D ES O, NCN, NSO2(ALQUILO C1-C3); A ES C, N, CH; M Y N SON 0-2; E ES N, CH, C; P ES 0-1; G, J Y E SON AX, AY, CUANDO P ES 1; CUANDO P ES 0, A ES C, Y G, J Y A SON AX, AY; AX ES HETEROCICLO DE 2 ANILLOS FUSIONADOS CON 5-7 MIEMBROS OPCIONALMENTE SUSTITUIDO; AY ES HETEROCICLO DE 4-6 MIEMBROS OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: ESTER DE METILO DEL ACIDO (±) -3-(3-CIANO-1H-INDOL-5-IL)-2-{[4-(2-OXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-IL)PIPERIDIN-1-CARBONIL]AMINO}-PROPIONICO; [2-[1,4´]BIPIPERIDINIL-1´-IL-1-(3-CIANO-1H-INDOL-5-ILMETIL)-2-OXO-ETIL}-AMIDA DEL ACIDO (±)-4-(2-OXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-IL)-PIPERIDIN-1-CARBOXILICO; ENTRE OTROS. REFERIDA TAMBIEN UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES PEPTIDOS RELACIONADOS CON EL GEN DE LA CALCITONINA (RECEPTOR CGRP) UTILES EN EL TRATAMIENTO DE LA VASODILATACION NEUROGENICA, MIGRANA Y PROBLEMAS RELACIONADOSREFERS TO A COMPOUND OF FORMULA (I), WHERE V IS -N (R1) (R2), OR4, WHERE R4 IS H, C1-C6 ALKYL, C1-C4 HALKYL, AMONG OTHERS; R1 AND R2 ARE EACH H, C1-C6 ALKYL, C2-C6 ALKYL, PHENYL, AMONG OTHERS; Q IS (SY) SR3, NH (SY) SR3, NHC (O) (SY) SR3, AMONG OTHERS; R3 IS C3-C7 CYCLOALKYL, CARBAZYL, PHENYL, AMONG OTHERS; SY IS C1-C3 ALKYLENE, C1-C3 ALKYLIDENE; S IS 0-1; U IS CH2, NH; D IS O, NCN, NSO2 (C1-C3 ALKYL); A IS C, N, CH; M AND N ARE 0-2; E IS N, CH, C; P IS 0-1; G, J AND E ARE AX, AY, WHEN P IS 1; WHEN P IS 0, A IS C, AND G, J AND A ARE AX, AY; AX IS 2-RING HETEROCYCLE FUSED WITH 5-7 MEMBERS OPTIONALLY REPLACED; AY IS HETEROCYCLE OF 4-6 MEMBERS OPTIONALLY REPLACED. PREFERRED COMPOUNDS ARE: ACID METHYL ESTER (±) -3- (3-CYAN-1H-INDOL-5-IL) -2 - {[4- (2-OXO-1,4-DIHIDRO-2H-QUINAZOLIN- 3-IL) PIPERIDIN-1-CARBONYL] AMINO} -PROPIONIC; [2- [1,4´] BIPIPERIDINYL-1´-IL-1- (3-CYANE-1H-INDOL-5-ILMETHYL) -2-OXO-ETHYL} -ACID AMIDE (±) -4- (2 -OXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-IL) -PIPERIDIN-1-CARBOXYL; AMONG OTHERS. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE ANTAGONISTS OF THE PEPTIDE RECEPTORS RELATED TO THE CALCITONIN GENE (CGRP RECEPTOR) USEFUL IN THE TREATMENT OF NEUROGENIC VASODILATION, MIGRANE AND RELATED PROBLEMS

PE2004001196A 2003-12-05 2004-12-06 PEPTIDE RECEPTOR ANTAGONISTS RELATED TO THE CALCITONIN GENE PE20051036A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/038799 WO2005065779A1 (en) 2003-12-05 2003-12-05 Calcitonin gene related peptide receptor antagonists

Publications (1)

Publication Number Publication Date
PE20051036A1 true PE20051036A1 (en) 2005-12-11

Family

ID=34748456

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001196A PE20051036A1 (en) 2003-12-05 2004-12-06 PEPTIDE RECEPTOR ANTAGONISTS RELATED TO THE CALCITONIN GENE

Country Status (15)

Country Link
EP (1) EP1689493A4 (en)
JP (1) JP2007524568A (en)
CN (1) CN100558428C (en)
AR (1) AR046788A1 (en)
AU (1) AU2003297694A1 (en)
BR (1) BR0318637A (en)
CA (1) CA2549330A1 (en)
IL (1) IL176018A0 (en)
IS (1) IS8482A (en)
NO (1) NO20062648L (en)
PE (1) PE20051036A1 (en)
RS (1) RS20060382A (en)
TW (1) TWI284534B (en)
UA (1) UA81563C2 (en)
WO (1) WO2005065779A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
JP4769082B2 (en) * 2003-12-17 2011-09-07 武田薬品工業株式会社 Urea derivatives, their production and use
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
JP2008510728A (en) 2004-08-19 2008-04-10 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
DE102005050892A1 (en) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US7473778B2 (en) * 2005-12-24 2009-01-06 Boehringer Ingelheim International Gmbh 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
JP2009527568A (en) 2006-02-22 2009-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
EP2225223B1 (en) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organic compounds
CN105012318B (en) * 2014-04-17 2020-02-11 沈华浩 Application of sulfonamide compound in airway chronic inflammatory diseases
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
CN117624191A (en) * 2022-08-30 2024-03-01 熙源安健医药（上海）有限公司 Indazole carboxamide derivatives, preparation method and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11512396A (en) 1995-09-05 1999-10-26 スミスクライン・ビーチャム・コーポレイション Compounds and methods
US5869489A (en) * 1996-03-25 1999-02-09 Merck & Co., Inc. Trypthophan ureas as neurokinnin antagonists
GB2311523A (en) * 1996-03-25 1997-10-01 Merck & Co Inc Tryptophan urea tachykinin receptor antagonists
CA2264942A1 (en) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
SK285631B6 (en) 1996-09-10 2007-05-03 Dr. Karl Thomae Gmbh Modified amino acids, pharmaceutical composition comprising its and its use
US6063796A (en) * 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6329389B1 (en) 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
AU6211499A (en) * 1998-09-30 2000-04-17 Merck & Co., Inc. Benzimidazolinyl piperidines as cgrp ligands
DE19911039A1 (en) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Modified amino acid amides, pharmaceutical compositions containing these compounds and process for their preparation
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
DE19952146A1 (en) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkanes, arylalkenes and aryl-azaalkanes, medicaments containing these compounds and process for their preparation
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
DE19963868A1 (en) 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma New substituted piperidines, pharmaceutical compositions containing these compounds and process for their preparation
WO2002022563A1 (en) * 2000-09-14 2002-03-21 Toray Industries, Inc. Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
ATE453661T1 (en) 2001-09-27 2010-01-15 Merck & Co Inc ISOLATED DNA MOLECULES ENCODING A HUMANIZED CALCITONIN GENE-RELATED PEPTIDE RECEPTOR, RELATED NON-HUMAN TRANSGENIC ANIMALS AND ASSAY METHODS
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10211770A1 (en) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Novel substituted piperidines, pharmaceutical compositions containing them and processes for their preparation
DK1539766T3 (en) * 2002-06-05 2017-04-03 Bristol Myers Squibb Co CALCITONIN GEN-RELATED PEPTIDE RECEPTOR ANTAGONISTS
DE10300973A1 (en) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New carboxylic acids and their esters, medicaments containing these compounds and processes for their preparation

Also Published As

Publication number Publication date
EP1689493A4 (en) 2008-04-23
EP1689493A1 (en) 2006-08-16
BR0318637A (en) 2007-02-13
WO2005065779A1 (en) 2005-07-21
JP2007524568A (en) 2007-08-30
IS8482A (en) 2006-05-26
CN100558428C (en) 2009-11-11
AR046788A1 (en) 2005-12-21
TW200529835A (en) 2005-09-16
TWI284534B (en) 2007-08-01
AU2003297694A1 (en) 2005-08-12
UA81563C2 (en) 2008-01-10
IL176018A0 (en) 2006-10-05
RS20060382A (en) 2008-09-29
CN1917921A (en) 2007-02-21
CA2549330A1 (en) 2005-07-21
NO20062648L (en) 2006-08-02

Similar Documents

Publication Publication Date Title
PE20051036A1 (en) PEPTIDE RECEPTOR ANTAGONISTS RELATED TO THE CALCITONIN GENE
PE20060286A1 (en) PIPERIDINE OR PIPERAZINE DERIVATIVES AS ANTAGONISTS OF THE CGRP RECEPTOR
US11707452B2 (en) Modulators of alpha-synuclein proteolysis and associated methods of use
US8003642B2 (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
AU2003284984B2 (en) Gamma-aminoamide modulators of chemokine receptor activity
US8143404B2 (en) Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
ES2864349T3 (en) New GLP-1 receptor modulators
FR2884516A1 (en) NPY ANTAGONISTS, PREPARATION AND USES
PE20060076A1 (en) MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS
DE3850203D1 (en) Benzimidazoline-2-oxo-1-carboxylic acid derivatives, usable as antagonists of 5-HT receptors.
PE20010628A1 (en) CYCLIC AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE
CN1143647A (en) Dipeptides which promote release of growth hormone
KR20120081609A (en) Novel compounds
PE20060722A1 (en) HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE CGRP RECEPTOR
SK8692002A3 (en) Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
ES2666188T3 (en) Beta-lactam vasopressin v1a antagonists
PE20040673A1 (en) DERIVATIVES OF CYCLOHEXYLUREA
PE20080311A1 (en) OXADIAZOLE DERIVATIVES AS RELATED AGENTS TO NICOTINE RECEPTORS
JP5123179B2 (en) Piperidine derivatives useful for the diagnosis and therapeutic treatment of diseases dependent on the activity of renin
JPH0892227A (en) Adhesion receptor antagonist
CA2294590A1 (en) Alpha 1a adrenergic receptor antagonists
PE20080206A1 (en) ARYL AND HETEROARYL-ETHYL-ACYLGUANIDINE DERIVATIVES AS RENIN INHIBITORS
US7176310B1 (en) Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
JP2012521350A (en) Amide derivatives as neuropeptide Y5 receptor ligands
CN1756747A (en) anti-inflammatory drugs

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed